Merck (MRK) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Feb 2, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Richard R. Deluca, Evp&Pres, Merck Animal Heallth sold 58,185 shares at $148.01 ($8.6M).
- Trade date
- Nov 12, 2026
- Disclosed to the SEC
- Nov 16, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All MRK insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
MRK insider transactions (Form 4)
Open-market purchases and sales. 57 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 16SEC | Richard R. DelucaEvp&Pres, Merck Animal Heallth | Sell | 58,185112,955 held (−34%) | $148.01 | $8.6M | -10.4% | — |
| Aug 13SEC | Jennifer ZacharyGeneral Counsel | Sell | 80,31545,509 held (−64%) | $133.46 | $10.7M | -0.7% | — |
| Aug 13SEC | Chirfi GuindoEvp, Access, Policy & Comms | Sell | 10,00036,613 held (−21%) | $135.00 | $1.4M | -1.8% | — |
| Aug 12SEC | Richard R. DelucaEvp&Pres, Merck Animal Heallth | Sell | 20,784134,703 held (−13%) | $130.43 | $2.7M | +1.6% | — |
| Aug 12SEC | Richard R. DelucaEvp&Pres, Merck Animal Heallth | Sell | 11,099110,767 held (−9%) | $131.61 | $1.5M | +0.7% | — |
| Aug 12SEC | Richard R. DelucaEvp&Pres, Merck Animal Heallth | Sell | 7,410127,293 held (−6%) | $131.33 | $973K | +1.0% | — |
| Aug 12SEC | Richard R. DelucaEvp&Pres, Merck Animal Heallth | Sell | 5,427121,866 held (−4%) | $132.35 | $718K | +0.2% | — |
| Aug 12SEC | Richard R. DelucaEvp&Pres, Merck Animal Heallth | Sell | 600110,167 held (−1%) | $132.04 | $79K | +0.4% | — |
| Aug 10SEC | Richard R. DelucaEvp&Pres, Merck Animal Heallth | Sell | 4,945155,787 held (−3%) | $130.23 | $644K | +1.8% | — |
| Aug 10SEC | Richard R. DelucaEvp&Pres, Merck Animal Heallth | Sell | 805160,732 held (−0%) | $131.02 | $105K | +1.2% | — |
| Aug 10SEC | Richard R. DelucaEvp&Pres, Merck Animal Heallth | Sell | 300155,487 held (−0%) | $131.02 | $39K | +1.2% | — |
| Aug 7SEC | David Michael WilliamsEvp,Chief Info&Digital Officer | Sell | 34,70531,716 held (−52%) | $128.77 | $4.5M | +3.0% | — |
| Aug 7SEC | Chirfi GuindoEvp, Access, Policy & Comms | Sell | 15,00046,613 held (−24%) | $131.00 | $2.0M | +1.2% | — |
| Aug 7SEC | David Michael WilliamsEvp,Chief Info&Digital Officer | Sell | 13,54231,716 held (−30%) | $128.77 | $1.7M | +3.0% | — |
| Aug 7SEC | David R. MaraldoEvp & Pres. Mmd | Sell | 9,70918,212 held (−35%) | $128.72 | $1.2M | +3.0% | — |
| Aug 7SEC | David R. MaraldoEvp & Pres. Mmd | Sell | 6,31118,212 held (−26%) | $128.72 | $812K | +3.0% | — |
| Aug 7SEC | David Michael WilliamsEvp,Chief Info&Digital Officer | Sell | 4,60031,716 held (−13%) | $128.77 | $592K | +3.0% | — |
| Aug 7SEC | David R. MaraldoEvp & Pres. Mmd | Sell | 2,68618,212 held (−13%) | $128.72 | $346K | +3.0% | — |
| Feb 12SEC | Chirfi GuindoChief Marketing Officer | Sell | 10,00060,615 held (−14%) | $121.46 | $1.2M | +9.2% | — |
| Feb 10SEC | Dean Y. LiPresident | Sell | 10,23592,035 held (−10%) | $117.52 | $1.2M | +12.8% | — |
| Feb 9SEC | Jennifer ZacharyGeneral Counsel | Sell | 56,79268,916 held (−45%) | $119.15 | $6.8M | +11.3% | — |
| Feb 9SEC | Jennifer ZacharyGeneral Counsel | Sell | 38,83568,916 held (−36%) | $119.15 | $4.6M | +11.3% | — |
| Feb 9SEC | Jennifer ZacharyGeneral Counsel | Sell | 25,94668,916 held (−27%) | $119.15 | $3.1M | +11.3% | — |
| Feb 9SEC | Chirfi GuindoChief Marketing Officer | Sell | 10,00070,615 held (−12%) | $118.41 | $1.2M | +12.0% | — |
| Feb 6SEC | Caroline LitchfieldCFO | Sell | 41,99790,192 held (−32%) | $119.61 | $5.0M | +10.8% | — |
| Feb 6SEC | Richard R. DelucaEvp&Pres, Merck Animal Heallth | Sell | 37,685160,174 held (−19%) | $120.92 | $4.6M | +9.6% | — |
| Feb 6SEC | Robert M. DavisCEO, President | Sell | 32,462443,602 held (−7%) | $118.35 | $3.8M | +12.0% | — |
| Feb 6SEC | Chirfi GuindoChief Marketing Officer | Sell | 20,00080,615 held (−20%) | $121.88 | $2.4M | +8.8% | — |
| Feb 6SEC | Johannes Jacobus OosthuizenPresident | Sell | 15,00021,197 held (−41%) | $121.87 | $1.8M | +8.8% | — |
| Feb 6SEC | Dean Y. LiPresident | Sell | 15,087102,270 held (−13%) | $118.77 | $1.8M | +11.6% | — |
| Feb 6SEC | Robert M. DavisCEO, President | Sell | 14,972476,064 held (−3%) | $117.38 | $1.8M | +12.9% | — |
| Feb 6SEC | David Michael WilliamsEvp,Chief Info&Digital Officer | Sell | 5,00030,838 held (−14%) | $121.91 | $610K | +8.8% | — |
| Feb 6SEC | Dalton E. Smart IIISvp Fin. - Global Controller | Sell | 4,00010,605 held (−27%) | $119.67 | $479K | +10.8% | — |
| Feb 6SEC | Dalton E. Smart IIISvp Fin. - Global Controller | Sell | 2,4008,205 held (−23%) | $119.67 | $287K | +10.8% | — |
| Nov 12SEC | Cristal N. DowningChief Comm. & Public Afrs Ofcr | Sell | 7,085 | $87.00 | $616K | +52.4% | — |
| Nov 4SEC | David Michael WilliamsEvp,Chief Info&Digital Officer | Sell | 8,61424,578 held (−26%) | $83.59 | $720K | +58.6% | — |
Similar past setups: not applicable. MRK has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with MRK in the Research Lab
MRK has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Merck insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 10 sold $79.3M of MRK stock on the open market; P/E 110.7 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
MRK insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $8.6M | 1 |
| Q3 2026 | — | 0 | $30.0M | 17 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $40.7M | 16 |
| Q4 2025 | — | 0 | $1.3M | 2 |
Valuation, profit and volume
Source: Yahoo Finance, as of Oct 5, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Merck & Co. insiders reported open-market purchases totaling $0, while 10 insiders reported sales totaling $79.3M. 0 of 36 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
MRK earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 29, 2026 | -0.7% | None | +6.1%S&P -2.1% | pending |
| Aug 4, 2026 | +0.2% | None | +0.4%S&P +1.6% | +17.1% |
| Apr 30, 2026 | -7.5% | None | +1.1%S&P +1.3% | +5.8% |
| Feb 3, 2026 | +4.2% | None | +4.4%S&P -1.3% | -2.1% |
| Oct 30, 2025 | +2.2% | None | -0.7%S&P -0.8% | +21.9% |
| Jul 29, 2025 | +0.8% | None | -2.7%S&P -0.4% | +2.9% |
| Apr 24, 2025 | -0.3% | None | +5.1%S&P +2.8% | -6.2% |
| Feb 4, 2025 | +1.9% | None | -10.1%S&P +1.1% | +5.6% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
MRK short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded MRK
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Sold $15,001 - $50,000 | Mar 27, 2026 | Jul 21, 2026 | +12.3% |
Insiders at Merck & Co.
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Jennifer ZacharyGeneral Counsel | — | $25.2M | Aug 13, 2026 | — | — |
| Richard R. DelucaEvp&Pres, Merck Animal Heallth | — | $19.9M | Nov 16, 2026 | — | — |
| Chirfi GuindoEvp, Access, Policy & Comms | — | $8.2M | Aug 13, 2026 | — | — |
| David Michael WilliamsEvp,Chief Info&Digital Officer | — | $8.1M | Aug 7, 2026 | — | — |
| Robert M. DavisCEO, President | — | $5.6M | May 1, 2026 | — | — |
| Caroline LitchfieldCFO | — | $5.0M | May 1, 2026 | — | — |
| Dean Y. LiPresident | — | $3.0M | May 1, 2026 | — | — |
| David R. MaraldoEvp & Pres. Mmd | — | $2.4M | Aug 7, 2026 | — | — |
| Johannes Jacobus OosthuizenEvp, Oncology & Int?L | — | $1.8M | May 1, 2026 | — | — |
| Dalton E. Smart IIISvp Fin. - Global Controller | — | $766K | May 5, 2026 | — | — |
| Cristal N. DowningChief Comm. & Public Afrs Ofcr | — | $616K | Nov 12, 2025 | — | — |
| Betty D. LarsonEvp, Chief Hr Officer | — | — | May 1, 2026 | — | — |
| Sanat ChattopadhyayExe V-P & Pres. Mmd | — | — | May 1, 2026 | — | — |
| Joseph RomanelliPresident | — | — | Jan 28, 2026 | — | — |
Board links: companies that share insiders with MRK
Directors and executives who filed Form 4s for MRK and another company in the last 12 months.
- DUKDuke Energy Robert M. Davis CEO, President here · Director at DUK · latest filing May 11, 2026
- VYLRVylor Johannes Jacobus Oosthuizen Evp, Oncology & Int?L here · Director at VYLR · latest filing Oct 26, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
MRK stock: common questions
Are Merck & Co. insiders buying MRK stock?
No. No Merck & Co. insider reported an open-market purchase of MRK in the past 12 months.
Are Merck & Co. insiders selling MRK stock?
10 insiders reported sales worth $79.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is MRK's P/E ratio?
MRK trades at about 110.7 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is MRK's 52-week range?
Over the past year MRK has traded between $92.26 and $155.53. It last closed at $132.58 on Nov 19, 2026.